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Abstract
Aims/hypothesis The Finnish diabetes risk questionnaire is
a widely used, simple tool for identification of those at risk
for drug-treated type 2 diabetes. We updated the risk
questionnaire by using clinically diagnosed and screen-
detected type 2 diabetes instead of drug-treated diabetes as
an endpoint and by considering additional predictors.
Methods Data from 18,301 participants in studies of the
Evaluation of Screening and Early Detection Strategies for
Type 2 Diabetes and Impaired Glucose Tolerance (DETECT-2)
project with baseline and follow-up information on oral
glucose tolerance status were included. Incidence of type 2
diabetes within 5 years was used as the outcome variable.
Improvement in discrimination and classification of the
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logistic regression model was assessed by the area under the
receiver-operating characteristic (ROC) curve and by the net
reclassification improvement. Internal validation was by
bootstrapping techniques.
Results Of the 18,301 participants, 844 developed type 2
diabetes in a period of 5 years (4.6%). The Finnish risk
score had an area under the ROC curve of 0.742 (95% CI
0.726–0.758). Re-estimation of the regression coefficients
improved the area under the ROC curve to 0.766 (95% CI
0.750–0.783). Additional items such as male sex, smoking
and family history of diabetes (parent, sibling or both)
improved the area under the ROC curve and net reclassi-
fication. Bootstrapping showed good internal validity.
Conclusions/interpretation The predictive value of the
original Finnish risk questionnaire could be improved by
adding information on sex, smoking and family history of
diabetes. The DETECT-2 update of the Finnish diabetes
risk questionnaire is an adequate and robust predictor for
future screen-detected and clinically diagnosed type 2
diabetes in Europid populations.
Keywords Epidemiology . Incidence . Prediction model .
Primary prevention . Type 2 diabetes
Abbreviations
DETECT-2 Evaluation of Screening and Early Detection
Strategies for Type 2 Diabetes and Impaired
Glucose Tolerance
ROC Receiver-operating characteristic
Introduction
Lifestyle and drug intervention in individuals at high-risk
for type 2 diabetes mellitus have been shown to be able to
prevent or delay the occurrence of type 2 diabetes [1, 2].
More specifically, lifestyle intervention was most effective
among individuals with a high score on the Finnish diabetes
risk tool that predicts the occurrence of type 2 diabetes [3].
Therefore, detection of high-risk individuals using a risk
score may be relevant to identify those who may benefit
most from interventions.
Next to existing risk scores to detect undiagnosed
diabetes [4–6], several investigators have developed risk
scores that predict incident diabetes [7–15]. Some of these
risk scores include genetic information [7], laboratory
measurements [8, 9] or systolic blood pressure [10] and
are therefore applicable in clinical practice only. Others
contain readily available information that is suitable for
self-report questionnaires [11–15]. The questionnaire ap-
proach has been used as a first step in risk assessment or
screening programmes because it does not require blood
testing and is therefore simple, short and inexpensive [16].
The Finnish diabetes risk score is a widely applied risk
score in Europid populations. The Finnish risk question-
naire has been shown to predict drug-treated type 2 diabetes
in Finland [11] and type 2 diabetes as diagnosed by an
OGTT in a Dutch population [17].
However, the Finnish risk questionnaire was developed
to predict drug-treated type 2 diabetes without screening
with an OGTT. It therefore seems appropriate to update it
using a combined endpoint of clinically diagnosed (not
only drug-treated) and screen-detected type 2 diabetes [18].
It is possible that the current risk questionnaire poorly
identifies people whose diabetes would not be diagnosed
and treated in clinical practice. For example, this may
concern those with isolated elevation of post-load glucose
levels, because an OGTT is usually not applied in general
practice. It has been shown that there is limited overlap
between fasting and post-load glucose levels; however,
post-load glucose levels are strongly associated with
cardiovascular risk [19]. Furthermore, the Finnish inves-
tigators had no information on family history of type 2
diabetes, hip circumference or smoking, which are poten-
tially important predictors [20–22]. Updating an existing
prediction tool instead of developing a new model may be a
good alternative with the advantage of combining prior
information on predictors with new data [23].
The aim of the present study was to update the Finnish
diabetes risk questionnaire for the prediction of future
clinically diagnosed and screen-detected type 2 diabetes and
to consider additional predictors in an international population.
Methods
Study population The Evaluation of Screening and Early
Detection Strategies for Type 2 Diabetes and Impaired
Glucose Tolerance (DETECT-2) project is an international
data-pooling collaboration addressing issues related to screen-
ing for type 2 diabetes [24]. Minimum requirements for
DETECT-2 participation were (1) population-based surveys
of large cohorts (n>500 people); (2) with all participants
without known diabetes having a 75 g OGTT to classify type
2 diabetes according to the WHO 2006 criteria [18].
For the present analysis, all centres in the DETECT-2
collaboration with published incidence rates of type 2
diabetes were asked for baseline and follow-up information
on oral glucose tolerance status. A total of six centres
located in Europe (Hoorn Study [25], Inter99 [26], The
Northern Sweden MONICA Study [27] and Whitehall-II
[28]), Australia (AusDiab [29]) and Africa (Mauritius [30]),
were included in the present analysis. Participation rates at
the follow-up examination ranged from 50% in NSW-
MONICA to 75% in Inter99.
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Of the 23,226 persons with information on glucose
tolerance status at follow up, we excluded 1,334 patients
with known diabetes at baseline, 985 patients with screen-
detected diabetes at baseline and 343 persons with missing
or incomplete information on glucose status at baseline,
leaving 20,564 participants for the present analysis. Partic-
ipants provided informed consent and the studies have been
approved by the relevant local ethics committees in accor-
dance with the Declaration of Helsinki (revision 2000).
Incidence of type 2 diabetes This was defined as self-
reported clinically diagnosed type 2 diabetes and/or screen-
detected type 2 diabetes at the follow-up examination as
defined by standard 75 g OGTT according to the WHO
2006 criteria [18]. To reach comparable follow-up periods
for each centre, the follow-up period for each individual
was truncated at 5 years after baseline and the assumption
was made that the date of type 2 diabetes diagnosis was in
the middle of the follow-up period. Hence, incident cases
are all persons who developed type 2 diabetes within
5 years after the baseline examination.
The Finnish diabetes risk score in DETECT-2 The Finnish
diabetes risk score predicts the incidence of drug-treated
type 2 diabetes within 10 years. The variables of the
Finnish diabetes risk score are: age (in categories <45; 45–
54; 55–64 and ≥65 years), BMI (in categories ≤25; 25–
29.99 and ≥30 kg/m2 and higher), waist circumference (in
categories for men: <94; 94–101.99 and ≥102 cm and for
women: <80; 80–87.99 and ≥88 cm), use of blood pressure
medication and history of high blood glucose [11]. Family
history of diabetes was proposed as an item of the original
Finnish risk score but the scores for parent or sibling
diabetes were based on literature reports, and no data were
available to verify the attributed score [11].
In the present analysis, if information on the use of blood
pressure medication was missing then we set this variable to
‘no’. Information on history of high blood glucose was
limited to the history of gestational diabetes. Multiple
imputations by chained equations were applied to eliminate
missing values on age (0.03%), BMI (0.4%), waist circum-
ference (0.6%) and history of gestational diabetes (missing in
four of the six centres=65% of the study population),
resulting in five imputed datasets. Regression coefficients
and standard errors of the predictors of type 2 diabetes in the
five imputed datasets were comparable to each other and to
the pooled estimates after applying Rubin’s rules, which
means that imputation variation was low. Therefore, we used
one randomly chosen imputed dataset for further analysis.
Updating The Finnish diabetes risk scores were re-
estimated by multiple logistic regression analysis with all
variables of the Finnish model.
Thereafter, relevant predictors (identified by a literature
search) were added one by one to the multiple logistic
regression model. These included sex, smoking, hip circum-
ference (in sex-specific tertiles), use of lipid-lowering medica-
tion and family history of diabetes (parent or sibling or both).
Finally, in additional analyses, we assessed an item of the Rose
questionnaire [31]: reported ‘shortness of breath when walking
with people of the same age’ as a potential predictor that was
available in two centres. Except for potential interactions with
study region, interactions were not considered because we
aimed to develop a risk score that was internationally
applicable and adding an interaction term would hamper the
practical feasibility of the model. We investigated whether
these variables improved the discriminative value of the
model. The discriminative value was assessed using the area
under the receiver-operating characteristic (ROC) curves,
plotting sensitivity against 1 – specificity. The area under the
ROC curve is a global summary statistic of the discriminative
value of a model, describing the probability that the score is
higher in an individual developing type 2 diabetes than in an
individual not developing type 2 diabetes. The difference
between models in area under the ROC curve was tested by a
method described by Hanley and McNeil [32]. To test model
goodness-of-fit we performed the Hosmer and Lemeshow test
[33]. We also calculated the net reclassification improvement
of the models that included additional predictors compared
with the model without the additional predictors according to
the method of Pencina et al. [34]. For that procedure, three
risk categories were chosen a priori: low risk (<10%),
intermediate risk (10–20%) and high risk (>20%).
Sensitivity analyses In sensitivity analyses, we assessed the
ability of the model to detect undiagnosed diabetes and to
predict future clinically diagnosed (i.e. without screen-
detected cases) diabetes.
Validation and comparison with existing risk scores It is
well-known that the apparent performance of a model is better
in the derivation dataset than in another dataset, which is
called overfitting. To estimate the amount of overfitting in the
regression coefficients and the area under the ROC curves,
bootstrapping techniques were used [35]. These bootstrap-
adjusted measures represent the values that can be expected
when the model is applied to future similar populations.
Therefore, 200 bootstrap samples of equal size to the original
dataset were drawn from the original dataset. The amount of
overfitting in regression coefficients can be estimated by the
slope index. The slope is calculated with the logistic
regression model and the linear predictor scores as the only
determinant. The linear predictor scores in each bootstrap
and original sample are calculated by multiplying the
model’s regression coefficients by the predictor values for
each patient and summing them (including the intercept).
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Ideally this slope is 1, which means that the model’s
predicted and observed probabilities agree over the whole
range of predictions. The difference in slope between the
bootstrap and original sample can then be used as a
shrinkage factor by multiplying the slope with each
regression coefficient in the original model [23]. Thereafter,
these bootstrap-adjusted regression coefficients were trans-
formed into scores, i.e. multiplied by 4 and rounded off for
simplicity to make the score values comparable to those of
the Finnish risk score. For each individual, the total risk
score can then be calculated by adding up the scores of each
separate item. The performance of the updated model was
compared with existing risk models for prevalent and
incident diabetes for which (almost complete) information
was available. Analyses were performed in SPSS 15.0.0
(SPSS, Chicago, IL, USA) and bootstrapping was performed
in R 2.9.0 for Windows.
Results
Characteristics of the study population for each centre are
given in Table 1. Because of interactions between almost all
risk predictors and the study region Mauritius, we excluded
this study cohort from further analyses. In total, the number
of persons who developed type 2 diabetes during the 5 year
follow up was 844 of 18,301 (4.6%). Incidence rate varied
from 4.6 to 20.6 per 1,000 person-years and was highest
among the older Hoorn study participants.
The Finnish diabetes risk score had an area under the
ROC curve of 0.742 (95% CI 0.726–0.758) in the whole
study population, ranging from 0.63 to 0.78 among centres.
Re-estimating the coefficients of the original Finnish score
showed that all variables of the Finnish risk model were
independent and significant predictors in the multiple
regression model (Table 2). Also, re-estimating the regres-
sion coefficients resulted in an improvement in the area
under the ROC curve (0.766 [95% CI 0.750–0.783])
compared with the original Finnish model (p<0.05).
Information on sex, smoking and hip circumference was
added one by one to the model. Male sex and smoking were
both significant predictors in the multiple model, contrib-
uting significantly to the area under the ROC curve (p<
0.05), compared with the re-estimated Finnish model.
However, hip circumference did not improve the area under
the ROC curve significantly.
Of those variables that were available in fewer than five
centres, a family history of diabetes was a significant
Table 1 Characteristics of the study populations
Characteristic AusDiab Inter99 Hoorn NSW-MONICA Whitehall II
Baseline (year) 1999–2000 1999–2001 1989–1991 1986–1999 1991–1993
N 5,660 4,510 1,353 1,544 5,234
Age (years) 51.2 (12.7) 46.3 (7.8) 60.3 (6.9) 47.6 (12.4) 49.1 (5.9)
Sex (% male) 44.4 49.9 45.6 47.7 71.6
BMI (kg/m2) 26.6 (4.6) 26.0 (4.3) 26.2 (3.1) 25.4 (3.8) 25.2 (3.6)
Waist circumference (cm) 89.6 (13.3) 85.9 (12.7) 89.6 (10.2) 86.7 (11.6) 83.7 (11.3)
Hip circumference (cm) 104.3 (9.4) 100.5 (9.3) 101.6 (6.3) 99.0 (7.3) 96.9 (7.1)
Former smoking (%) 29.1 26.7 34.4 26.4 35.4
Current smoking (%) 11.4 34.6 30.1 17.8 11.4
Use of anti-hypertensives (%) 12.8 6.1 15.8 8.3 6.5
Use of lipid-lowering treatment (%) 6.9 1.0 1.4 0.6 0.8
History of gestational diabetes (%) 1.8 2.2 a 0.9 1.4a 0.5 a
Parent only with diabetes (%) 17.1 12.7 12.2 – –
Sibling only with diabetes (%) – 2.5 4.4 – –
Parent and sibling with diabetes (%) – 1.6 2.5 – –
Shortness of breath when walking (%) – 1.6 5.6 – –
Follow-up
Period at risk (years) 4.9 (0.6) 4.9 (0.6) 4.8 (0.6) 5.0 (0.3) 5.0 (0.3)
5-year incidence, n/Nb (%) 335/5,660 (5.9) 207/4,510 (4.6) 134/1,353 (9.9) 48/1,544 (3.1) 120/5,234 (2.3)
Incidence rate per 1,000 person-yearsc 12.1 9.4 20.6 6.2 4.6
a By multiple imputation
bN is the number of participants in the study, n is the number of incident cases
c Estimated incidence rate in cases per 1,000 person-years was calculated by assumption that the date of type 2 diabetes diagnosis was in the middle of the
follow-up period
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predictor in the multiple model (Table 2) and contributed to
the area under the ROC curve on top of the re-estimated
model including sex and smoking (p<0.05). In contrast,
information on the use of lipid-lowering medication did not
statistically significantly change the area under the ROC
curve. The full, extended model included three additional
variables to the Finnish risk model; sex, smoking and
family history of diabetes. In the three centres that had
information on all variables, the area under the ROC curve
improved from 0.754 (95% CI 0.735–0.773) to 0.764 (95%
CI 0.746–0.783, p<0.05) ranging from 0.70 to 0.78 among
centres (Fig. 1). Some heterogeneity between study region
and risk predictors was found, as observed by the range in
coefficients among centres, but this could not be attributed
to one specific study centre (Table 2). As indicated by non-
overlapping confidence intervals, the regression coefficient
for age (category 45–55 years) was lower in AUSDIAB, the
coefficient for BMI (≥30 kg/m2) was lower in Hoorn and
the coefficient for history of gestational diabetes was higher
in AUSDIAB. The Hosmer and Lemeshow test results
showed good calibration (χ2=10.0, p=0.27, Fig. 2).
Reclassification improved by 7.3% among persons who
developed diabetes and worsened by 1.0% among persons
who did not develop diabetes, so net reclassification was
6.3% (p<0.001) compared with the re-estimated Finnish
model.
Sensitivity analyses Because the present risk model was
developed as a risk questionnaire, which is often used as a
first step in risk assessment, prevalent undiagnosed type 2
Table 2 Multiple logistic regression models predicting 5 year incidence of type 2 diabetes in the DETECT-2 cohort (n=18,301)
Variable Re-estimated Finnish risk
model
Extended model Extended model including
family historya
Range in coefficients
among centresb
Score
pointsc
Regression
coefficient
OR (95% CI) Regression
coefficient
OR (95% CI) Regression
coefficient
OR (95% CI)
Age (years)
<45 0 1 0 1 0 1 – 0
45–55 0.248 1.28 (1.05–1.57) 0.267 1.31 (1.06–1.61) 0.280 1.32 (1.05–1.67) –0.130 to 0.513 1
55–65 0.578 1.78 (1.44–2.20) 0.628 1.87 (1.51–2.33) 0.572 1.77 (1.39–2.27) 0.304–1.177 2
≥65 0.860 2.36 (1.82–3.07) 0.953 2.59 (1.99–3.39) 0.835 2.30 (1.73–3.07) 0.472–1.808 4
BMI (kg/m2)
<25 0 1 0 1 0 1 – 0
25–29.99 0.329 1.39 (1.12–1.73) 0.261 1.30 (1.04–1.63) 0.180 1.20 (0.93–1.55) –0.015 to 0.703 1
≥30 0.508 1.66 (1.25–2.22) 0.485 1.62 (1.21–2.18) 0.354 1.43 (1.02–1.99) –0.461 to 1.106 2
Waist circumference (cm)
Female <80; male <94 0 1 0 1 0 1 – 0
Female 80–87.99; male
94–101.99
0.355 1.43 (1.14–1.79) 0.397 1.49 (1.18–1.88) 0.201 1.22 (0.94–1.60) 0.098–0.552 2
Female ≥88; male ≥102 1.050 2.86 (2.23–3.66) 1.121 3.07 (2.37–3.98) 0.958 2.61 (1.94–3.50) 0.556–1.628 4
Use of anti-hypertensives 0.698 2.01 (1.67–2.43) 0.727 2.07 (1.71–2.50) 0.749 2.12 (1.71–2.61) 0.368–0.936 3
History of gestational
diabetes
3.101 22.23 (16.82–
29.37)
3.140 23.10 (17.30–
30.83)
2.835 17.02 (12.32–
23.54)
–0.101 to 5.491 12
Sex (male vs female) – – 0.259 1.30 (1.11–1.51) 0.357 1.43 (1.20–1.70) 0.033–0.705 1
Smoking
Former smoking – – 0.149 1.16 (0.98–1.38) 0.180 1.20 (0.98–1.46) –0.027 to 0.159 1
Current smoking – – 0.563 1.76 (1.45–2.12) 0.521 1.68 (1.37–2.08) –0.285 to 0.575 2
Family history of diabetesd
Parent only with diabetes – – – – 0.648 1.91 (1.56–2.33) 0.612–0.874 3 e
Sibling only with diabetes – – – – 0.759 2.14 (1.28–3.57) 0.211–1.042 3 e
Parent and sibling with
diabetes
– – – – 0.926 2.53 (1.38–4.62) 0.764–1.061 4 e
a This extended model is estimated in the three centres (n=11,523) that had information on family history of diabetes available
b Five study centres for all variables except for family history of diabetes, for which the range among three centres that had this information available is
shown
c Score points are calculated from the extended model as: regression coefficient × slope index (=0.974) × 4, and rounded off for simplicity
d The score for this item is 4 at maximum, someone can have no family members or a parent only or a sibling only or both a parent and a sibling with
diabetes
e The score points for family history only were estimated in three centres that had this information available
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diabetes may remain undiagnosed. Therefore, we assessed
to what extent the present developed model is able to detect
prevalent, screen-detected type 2 diabetes. Prevalent undiag-
nosed type 2 diabetes was equally well predicted as incident
type 2 diabetes by the present model (area under the ROC
curve 0.765 [95% CI 0.746–0.783] as compared with 0.764
[95% CI 0.746–0.783] for incident type 2 diabetes).
The performance of the updated risk model to predict
future clinically diagnosed cases only was higher than if
clinically diagnosed and screen-detected patients were
predicted together (area under the ROC curve 0.787 [95%
CI 0.760–0.814] for clinically diagnosed only compared
with 0.764 [95% CI 0.746–0.783]).
Validation and comparison with existing risk scores Com-
parison of bootstrap-adjusted areas and the original areas
under the ROC curve showed only a marginal difference.
The area under the ROC curve of the extended model
decreased from 0.764 (95% CI 0.746–0.783) to 0.759 (95%
CI 0.739–0.779). Bootstrap-adjusted regression coefficients
were also marginally smaller than the original coefficients
(slope index 0.974, Table 2).
The original Finnish risk score and the updated score
performed better than existing risk scores for prevalent or
incident type 2 diabetes. The area under the ROC curve of
the Framingham Offspring Study [13] was 0.658 (95% CI
0.637–0.679), of the Aekplakorn et al. risk score [14] 0.654
(95% CI 0.633–0.675), of Cambridge risk score [4] without
information on use of steroids 0.669 (95% CI 0.647–0.691)
and of the Danish diabetes risk score [5] without informa-
tion on physical activity 0.665 (95% CI 0.643–0.687).
Cut-off points Test characteristics for a range of cut-off
values are presented in Table 3. At a score of 7 or higher,
the sum of sensitivity and specificity was maximised. Of
the total population, 40% had a score of 7 or higher. A
score of 7 or higher captures 76% of the cases who will
develop type 2 diabetes (sensitivity). Furthermore, 63% of
the persons who do not develop type 2 diabetes had a score
lower than 7 (specificity).
Additional analyses Information on self-reported shortness
of breath when walking was evaluated as a risk
predictor in two centres (Inter99 and Hoorn). This item
was a significant predictor in the multiple model but
adding information on this item to the extended model
did not improve discrimination (p>0.05) or net reclassi-
fication (p>0.05).
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Fig. 2 Observed and expected risk for developing type 2 diabetes (%)
in deciles of expected risk according to the extended model in three
centres (n=11,523) with information on the extended model including
family history; grey bars, observed risk; black bars, expected risk
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Fig. 1 ROC curve of the extended model (AUC 0.764 [95% CI
0.746–0.783]) compared with the re-estimated model (AUC 0.742
[95% CI 0.723–0.762]) and the original Finnish model (AUC 0.712
[95% CI 0.692–0.731]) in three centres (n=11,523) with information
on the extended model including family history. Light grey line,
original Finish risk score; medium grey line, re-estimated score, black
line, extended score
Table 3 Sensitivity, specificity and positive predictive value for
various cut-off values in a subsample of three centres with information
on the extended model including family history
Score Percentage
of the
population
Sensitivity
(%)
Specificity
(%)
Positive
predictive
value (%)
4 or higher 68 91 33 8
5 or higher 58 88 44 9
6 or higher 49 84 54 10
7 or higher 40 76 63 11
8 or higher 30 66 72 13
9 or higher 22 57 80 15
10 or higher 16 48 86 17
11 or higher 11 37 90 19
12 or higher 8 31 94 23
13 or higher 5 23 96 26
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Discussion
The present dataset is derived from a large data pooling
collaboration containing five cohort studies with information
on glucose tolerance status based on an OGTT. This provides
an excellent opportunity to assess screen-detected next to
clinically diagnosed incident diabetes and as such to validate
and update the widely used Finnish diabetes risk score.
We showed that the Finnish score was already a good
predictor for clinically diagnosed and screen-detected type
2 diabetes. Also, adding easily accessible information on
sex, smoking and family history of diabetes improved the
test’s predictive power.
The present study differs from the Finnish study with
respect to both population characteristics and the way that
type 2 diabetes was diagnosed [11], for this reason we
cannot simply ascribe the observed differences to the
inclusion of screen-detected incident type 2 diabetes in
our endpoint. Nevertheless, the present definition including
screen-detected and clinically diagnosed type 2 diabetes
involves more patients than the drug-treated patients that
were predicted by the original Finnish score. Drug-treated
patients probably have more advanced diabetes than screen-
detected patients or patients treated by lifestyle only. This
may at least in part, explain the lower discrimination of the
present risk score as compared with the original Finnish
risk score in the Finnish study in which it was developed.
Indeed, the present risk score also predicted clinically
diagnosed patients better than screen-detected patients. We
think however that use of the present definition of type 2
diabetes is an improvement because it will also detect
future diabetes patients who are less likely to be detected by
general practice, for example because of isolated elevation
of post-load glucose levels. This will lead to the identifi-
cation of a population that may benefit from preventive
interventions given their high cardiovascular risk [19, 36].
One advantage of updating an existing model instead of
developing a new one is that it combines earlier information
with new information. Updating methods vary from re-
calibration to extensive revision: re-estimation of regression
coefficients and consideration of new predictors [23]. As
we also used a different definition of the endpoint, and our
dataset had sufficient power, we chose to extensively
update this model.
Recent assessment, especially of new biomarkers for
cardiovascular disease, have shown that measures of
discrimination, calibration and reclassification are, when
used in isolation, not sufficient to decide whether one
model is superior to another [34]. Therefore, we used more
than one of these measures to decide whether or not to
include additional risk factors.
In the present analysis, we excluded patients with
prevalent known or screen-detected type 2 diabetes.
However, because the questionnaire usually serves as a
first step in risk assessment, prevalent type 2 diabetes may
remain undiagnosed. Therefore, the predictive value for
prevalent undiagnosed type 2 diabetes was also evaluated,
which showed equally good performance of the model for
prevalent undiagnosed and incident type 2 diabetes.
We evaluated the concise Finnish risk model instead of
the full risk model, which also includes physical activity
and daily consumption of vegetables, fruit or berries [11].
The main reason for this is the lack of information in the
present dataset. Furthermore, it is uncertain whether asking
one isolated question about diet or physical activity is
predictive for type 2 diabetes, taking into account that for
the development of the original risk model, these items
were obtained from an extensive questionnaire. Finally,
even when obtained from an extensive questionnaire, the
items on physical activity and diet only minimally
improved prediction [11].
We previously reported that the proposed score points
associated with the presence of one family member with
diabetes were relatively high (5 compared with the present
3 for parent or sibling) [17]. We also found that someone
with a sibling with diabetes is at similar risk to someone
with a parent with diabetes. Data on this are scarce, but this
finding is in line with a study among older Australians who
reported no consistent difference in the risk between those
with parental and sibling history of type 2 diabetes [37] but
contradicts a study among ethnic Chinese people [38]. The
difference between the studies may relate to age of onset of
diabetes in the family members. Among younger people, a
sibling with diabetes is likely to have developed diabetes at
a younger age than a parent with diabetes, and hence may
reflect a greater risk. However, among older adults, there is
less likely to be a difference in age of onset between
siblings and parents with diabetes. Furthermore, we found
that the presence of both a parent and a sibling with
diabetes greatly increases the risk for diabetes. This graded
effect of family history on risk for diabetes was pointed out
by the NHANES investigators [39].
Our study obviously has some limitations. First,
although especially the case for smaller datasets, external
validation is needed before implementing a prediction
model. It is well-known that the performance of a
prediction model is generally higher in the development
dataset than in another dataset, especially when the
population differs (in time or place) from the original
population. However, to some extent, external validation
can be studied by testing the performance of the model in a
non-random selection of the population, which was done
here by separate assessments of the performance in each
study centre. This showed good performance, which is
promising for external application of the model. Second,
although we showed good model performance in Europids,
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extrapolation to other populations should be done with
caution. Indeed, we found different associations between
risk predictors and incident type 2 diabetes in the Mauritius
cohort and therefore excluded the latter from the present
analysis. Recalibration of the score in other populations
would probably lead to more precise risk estimates and is
therefore indicated if data are available. Ethnicity within
England and Wales has indeed been shown to be an
important predictor for future drug-treated type 2 diabetes
[15]. In the same study, socioeconomic differences were
also found to be predictive. Studies are needed to assess
whether ethnic and socioeconomic measures would im-
prove existing models in the developing world. Third, the
characteristics of participants of current population-based
cohort studies may differ from the characteristics of people
participating in real-life step-wise screening programmes
because attendance rate for screening programmes is
generally low [40]. Selective participation of those at lower
risk for example will reduce the positive predictive value of
a risk score. Selective participation was not observed in the
ADDITION-Denmark study, using a mail-distributed risk
chart as a first screening step [40]. Instead, overall
participation rate was low, which indicated that one of the
major challenges in implementing primary prevention
programmes is to reach appropriate attendance rates.
Fourth, although test characteristics of the present score
show good results, follow-up measurements will be
indicated for a substantial part of the population (40%),
which has important implications for healthcare. However,
of this high-risk population, 11% will indeed develop
diabetes within the relatively short timeframe of 5 years
whereas lifetime diabetes risk will be higher. Further,
diabetes risk scores have also been shown to predict
cardiovascular disease [41, 42]. Thus, the 11% of the
high-risk population that will develop diabetes within
5 years is the minimum that will benefit from timely
intervention. Fifth, the WHO definition of type 2 diabetes
requires two abnormal glucose values for the diagnosis of
type 2 diabetes without symptoms [18]. Our diagnosis of
type 2 diabetes is based on one OGTT only. To our
knowledge, no observational studies have information on
the incidence of type 2 diabetes measured by duplicate
OGTT, so the present data are the best estimate of OGTT-
based incidence of type 2 diabetes currently available.
The present risk questionnaire may serve as a first
assessment tool identifying those who may need further
blood testing, probably not limited to glucose testing alone.
Integrated prevention strategies and targeted interventions
should also involve blood pressure and lipid levels because
these risk factors are highly inter-related. Future research
may aim to develop questionnaires that predict overall risk,
including cardiovascular disease risk.
To conclude, the predictive value of the original Finnish
risk questionnaire for clinically diagnosed and screen-
detected type 2 diabetes could be improved by re-
estimation of the score points and by additional information
on sex, smoking and family history of diabetes. The
DETECT-2 update of the Finnish diabetes risk question-
naire is an adequate and robust risk score to predict future
type 2 diabetes in Europid populations.
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